Table 1 Demographic characteristics of patients with rheumatic diseases and controls
Sum | Controls | Adolescents with RD | p | |
|---|---|---|---|---|
n | 64 | 24 | 40 | |
Age | ||||
(median, range) | 14 (12 – 16) | 13 (12 – 14) | 14 (13 – 16) | 0.07 |
Sex | ||||
Female n (%) | 34 (53%) | 12 (50%) | 22 (55%) | 0.79 |
Description of patients with rheumatic diseases: | ||||
Diagnosis n (%) | ||||
JIA | 26 (65%) | |||
joSLE | 6 (15%) | |||
Uveitis | 3 (7.5%) | |||
JDM | 1 (2.5%) | |||
Juvenile Systemic sclerosis | 1 (2.5%) | |||
Crohn´s disease | 1 (2.5%) | |||
Behçet`s disease | 1 (2.5%) | |||
HA20 | 1 (2.5%) | |||
Treatment n (%) | ||||
Adalimumab | 11 (27.5%) | |||
Etanercept | 9 (22.5%) | |||
Infliximab | 3 (7.5%) | |||
Mycophenolate | 5 (12.5%) | |||
Baricitinib | 5 (12.5%) | |||
Tocilizumab | 1 (2.5%) | |||
Cyclosporine | 1 (2.5%) | |||
None of the above | 5 (12.5%) | |||
Methotrexate | 14 (35%) | |||
Disease Activity n (%) | ||||
Inactive disease (VASc = 0) | 26 (65%) | |||
Active disease (VASc > 0) | 14 (35%) | |||